VEGFA and neoplasm: Based on our previous findings in tumor xenografts [12], showing that glycolytic tumors could better respond to antiangiogenic therapy, our working hypothesis was that certain variants could interfere with the physiological activity of mitochondrial complexes thus producing a distinct glycolytic metabolic signature, and tested whether these metabolic traits might render cancer cells more sensitive to anti-VEGF therapy in experimental tumor models.